SUSCEPTIBILITY TO MALIGNANT HYPERTHERMIA: CLINICAL EXOME PANEL (Sec. & CNVs) – 3 genes
Delivery time
3-4 weeks
Sample
Blood
The Malignant Hyperthermia Susceptibility Panel is designed to detect genetic variants associated with this potentially fatal pharmacogenetic reaction, triggered by volatile anesthetics or depolarizing muscle relaxants. Malignant hyperthermia is characterized by hypercapnia, muscle rigidity, tachycardia, metabolic acidosis, and rapidly progressive hyperthermia during general anesthesia. Identifying mutations in genes encoding calcium channels and proteins related to muscle contraction allows for the assessment of individual risk of developing the disease, guides anesthetic selection, and enables the implementation of preventive measures. Genes analyzed: RYR1, CACNA1S, STAC3. You can consult the complete list of analyzed genes by contacting Genotica.
Other tests
Exome panel analysis of 29 genes - idiopathic pulmonary fibrosis and surfactant protein deficiency
990,00€
511 gene analysis - epilepsy (using exome sequencing)
1.495,00€
Exome analysis of AGXT, GRHPR, and HOGA1 genes - primary hyperoxaluria
690,00€